Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.

Journal of clinical pharmacology - 1 Nov 2024

Liu Xiaomei I, Green Dionna J, van den Anker John, Calderon Joaquin, Ahmadzia Homa, Burckart Gilbert J, Dallmann André

Abstract excerpt

As detailed information on the pharmacokinetics (PK) of labetalol in pregnant people are lacking, the aims of this study were: (1) to build a physiologically based PK (PBPK) model of labetalol in non-pregnant individuals that incorporates different CYP2C19 genotypes (specifically, *1/*1, *1/*2 or *3, *2/*2, and *17/*17); (2) to translate this model to the second and third trimester of pregnancy; and (3) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Blood Pressure
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CYP2C19 gene

Share to Genotype

Share to Polymorphism, Genetic

Share to Pregnancy

Source

Open in PubMed Open full text

Identifiers

PMID: 38973651
DOI: 10.1002/jcph.2496
PMCID: PMC13185004

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.PMID 38973651Read ↗

When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.Semantic proximity Read ↗

An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomicsSemantic proximity Read ↗

CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.Semantic proximity Read ↗

Mechanisms of altered hepatic drug disposition during pregnancy: small moleculesSemantic proximity Read ↗

Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.Semantic proximity Read ↗

Pharmacokinetic Changes and Seizure Outcomes in Pregnant Women Taking Second-Generation Antiepileptic DrugsSemantic proximity Read ↗

Regulation of drug transporter expression and function in the placentaSemantic proximity Read ↗

UGT polymorphisms and lamotrigine clearance during pregnancy.Semantic proximity Read ↗

Changes in Expression and Function of Placental and Intestinal P-gp and BCRP Transporters during PregnancySemantic proximity Read ↗

ATP-Binding Cassette Efflux Transporters in Human PlacentaSemantic proximity Read ↗

Medicines in pregnancySemantic proximity Read ↗

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.